Business
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing se
About this update from Piramal Pharma Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand.","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development.","length":180,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":375,"olType":false},{"type":"text","content":"MUMBAI, India, Aug. 21, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need.","length":775,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Piramal Pharma Solutions)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Piramal Pharma Solutions)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":186,"url":"https://media.zenfs.com/en/cnwgroup.com/cfa3acd877db41da8f38ba0a065c0d07"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p4hsToyfacdojN3saot3_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMyODtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/cfa3acd877db41da8f38ba0a065c0d07","width":400,"height":186}},"href":"https://mma.prnewswire.com/media/1726186/Piramal_Pharma_Solutions_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination produ...